The Medicines Co (The Medicines Co) EPS (Basic) : $-3.10 (TTM As of Sep. 2019)

View and export this data going back to 2000. Start your Free Trial

What is The Medicines Co EPS (Basic)?

The Medicines Co's basic earnings per share (Basic EPS) for the three months ended in Sep. 2019 was $-0.92. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2019 was $-3.10.

The Medicines Co's EPS (Diluted) for the three months ended in Sep. 2019 was $-0.92. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was $-3.10.

The Medicines Co's EPS without NRI for the three months ended in Sep. 2019 was $-0.92. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2019 was -3.12.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

The Medicines Co EPS (Basic) Historical Data

The historical data trend for The Medicines Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Medicines Co EPS (Basic) Chart

The Medicines Co Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

EPS (Basic)

Get a 7-Day Free Trial

-0.50

-5.28

-1.71

-9.79

-1.68

The Medicines Co Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
EPS (Basic)	Get a 7-Day Free Trial															-0.75	-0.58	-0.80	-0.80	-0.92

The Medicines Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

The Medicines Co's Basic EPS for the fiscal year that ended in Dec. 2018 is calculated as

Basic EPS (A: Dec. 2018 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-123.156	-	0)	/	73.571
	=	-1.67

The Medicines Co's Basic EPS for the quarter that ended in Sep. 2019 is calculated as

Basic EPS (Q: Sep. 2019 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-73.994	-	0)	/	80.129
	=	-0.92

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.10

The Medicines Co (NAS:MDCO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

The Medicines Co EPS (Basic) Related Terms

Thank you for viewing the detailed overview of The Medicines Co's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

The Medicines Co (The Medicines Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » The Medicines Co (NAS:MDCO) » Definitions » EPS (Basic)

Traded in Other Exchanges

N/A

Address

8 Sylvan Way, Parsippany, NJ, USA, 07054

Website

https://www.themedicinescompany.com

The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.

Executives

Alexander J Denner	director	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Peter Wijngaard	officer: Chief Development Officer	8 SYLVAN WAY, PARSIPPANY NJ 07054
Paris Panayiotopoulos	director	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Geno J Germano	director	5 GIRALDA FARMS, MADISON NJ 07940
Sarah J. Schlesinger	director	C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christopher T Cox	officer: EVP & Chief Corp. Dev. Officer	CADWALADER, WICKERSHAM & TAFT LLP, ONE WORLD FINANCIAL CENTER, NEW YORK NY 10281
Fredric N Eshelman	director, officer: Executive Chairman	PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Armin M Kessler	director
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Hiroaki Shigeta	director	THE MEDICINES COMPANY, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Stuart A Kingsley	officer: President and COO	152 CHESTNUT STREET, WEST NEWTON MA 02465
Robert G. Savage	director	C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Glenn Sblendorio	director, officer: President & CFO	3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
James E Flynn	10 percent owner, other: Possible Members of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C)	10 percent owner, other: Possible Members of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010